MOLECULAR MECHANISMS OF ESTROGEN-REGULATED BONE RESORPTION

雌激素调节骨吸收的分子机制

• 批准号: 7960110
• 负责人: Darrin Lee DeMoss
• 金额: $ 21.61万
• 依托单位: UNIVERSITY OF LOUISVILLE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-08-22 至 2010-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7960110
• 关键词: Age-Months; Biomedical Research; Bone Resorption; Calcium Channel; Computer Retrieval of Information on Scientific Projects Database; Diltiazem; Estrogens; Female; Funding; Grant; Hormone replacement therapy; Institution; Molecular; Nifedipine; Research; Research Personnel; Resources; Source; United States National Institutes of Health; Verapamil

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective of this project is to enhance our understanding of the mechanisms of increased bone resorption, which accompanies estrogen deficiency. Bone resorption parameters have been compared between control females six months of age, ovariectomized females (OVX), females receiving hormone replacement therapy (HRT), and females receiving a calcium channel antagonists (Diltiazem, Nifedipine, Verapamil), or females receiving a combination of the two agents.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这个项目的主要目的是提高我们对雌激素缺乏引起骨吸收增加的机制的理解。 比较了6个月龄对照雌性动物、卵巢切除雌性动物（OVX）、接受激素替代治疗（HRT）的雌性动物和接受钙通道拮抗剂（地尔硫卓、硝苯地平、维拉帕米）的雌性动物或接受两种药物联合治疗的雌性动物的骨吸收参数。